Gain expert insights on current best practices for therapeutic drug monitoring in patients with IBD.
In this engaging, interactive, on-demand webcast, expert faculty review the rationale and current best practices for therapeutic drug monitoring (TDM) in patients with IBD. The data-driven discussion includes proactive and reactive TDM approaches for both TNF inhibitors and non-TNF inhibitor biologics.
Two experts offer practical considerations for monitoring antidrug antibodies in patients with inflammatory bowel disease receiving anti-TNF therapy.
Should you screen every patient with inflammatory bowel disease for HLA-DQA1*05? Here’s our take.